Spots Global Cancer Trial Database for Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Official Title: Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Study ID: NCT05846971
Interventions
Study Description
Brief Summary: Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.
Detailed Description: Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions for virtual patient cases when presented with different clinical and prognostic assay information. The data from this study will be published in a peer-review scientific journal.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Capsulomics, Inc., Baltimore, Maryland, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
